Introduction
infections, tissue damage, coronavirus disease 2019
DISEASE, CORONAVIRUS DISEASE 2019, INFECTIONS, INFLAMMATORY RESPONSES
The coronavirus disease 2019 (COVID-19) pandemic, which began in late 2019 in Wuhan, China, has led to more than 600 million infections and 6 million deathsAs clinical experience increases, opportunities for understanding the relationship between COVID-19 symptoms and clinical outcomes are growingInnate and adaptive immune responses, and the attendant cytokine profile, are critical for the effective clearance of SARS-CoV-2. However, these inflammatory responses may drive symptoms, and a prolonged response may be responsible for the tissue damage observed in severe COVID-19CAS + IMD (REGEN-COV®), comprising a combination of two monoclonal antibodies (casirivimab and imdevimab) targeting the receptor-binding domain of the SARS-CoV-2 spike protein, was developed for the treatment or prevention of COVID-19. In combination, these two antibodies exhibited strong in vitro neutralization of SARS-CoV-2 to prevent disease in non-human primates, and to prevent rapid mutational escape observed with individual antibodies in vitro